PRESS RELEASE
Q2 2023 — Press release
Q2 2023PDF · 24 pages1.2 MB
FOR IMMEDIATE RELEASE • 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* • Earnings per share (EPS) of $1.96 increasing 8.9% and adjusted EPS of $2.80 increasing by 8.1%* • Company is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding COVID-19 Vaccine and adjusted operational EPS • Johnson & Johnson intends to "split off" Kenvue shares through an exchange offer as the form of its next step in the separation, subject to market conditions New Brunswick, N.J. (July 20, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for second- quarter 2023. “Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation.” OVERALL FINANCIAL RESULTS Q2 ($ in Millions, except EPS) 2023 2022 % Change Reported Sales $25,530 $24,020 6.3% Net Earnings/(Loss) $5,144 $4,814 6.9% EPS (diluted) $1.96 $1.80 8.9% Q2 Non-GAAP* ($ in Millions, except EPS) 2023 2022 % Change Operational Sales1,2 7.5% Adjusted Operational Sales1,3 6.2% Adjusted Net Earnings1,4 $7,358 $6,912 6.5% Adjusted EPS (diluted)1,4 $2.80 $2.59 8.1% 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items Note: values may have been rounded -- 1 of 24 -- REGIONAL SALES RESULTS Q2 % Change ($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted Operational1,3 U.S. $13,444 $12,197 10.2% 10.2 - 8.0 International 12,086 11,823 2.2 4.7 (2.5) 4.4 Worldwide $25,530 $24,020 6.3% 7.5 (1.2) 6.2 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: Values may have been rounded SEGMENT SALES RESULTS Q2 % Change ($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted Operational1,3 Consumer Health $4,011 $3,805 5.4% 7.7 (2.3) 7.7 Pharmaceutical 13,731 13,317 3.1 3.8 (0.7) 3.9 MedTech 7,788 6,898 12.9 14.7 (1.8) 9.9 Worldwide $25,530 $24,020 6.3% 7.5 (1.2) 6.2 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: Values may have been rounded -- 2 of 24 -- SECOND QUARTER 2023 SEGMENT COMMENTARY: Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency. Pharmaceutical Pharmaceutical worldwide adjusted operational sales grew 3.9%*. Excluding the COVID-19 Vaccine, adjusted operational sales grew 6.2%*. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), and CARVYKTI (ciltacabtagene autoleucel) in Oncology, STELARA (ustekinumab) and TREMFYA (guselkumab) in Immunology, UPTRAVI (selexipag) and OPSUMIT (macitentan) in Pulmonary Hypertension, and SPRAVATO (esketamine) in Neuroscience. Growth was partially offset by ZYTIGA (abiraterone acetate) and IMBRUVICA (ibrutinib) in Oncology, COVID-19 Vaccine (Ad26.COV2.S) in Infectious Diseases, and REMICADE (infliximab) in Immunology. MedTech MedTech worldwide adjusted operational sales grew 9.9%*, driven primarily by electrophysiology products in Interventional Solutions, trauma in Orthopaedics, wound closure products in General Surgery, biosurgery in Advanced Surgery, and contact lenses in Vision. MedTech worldwide operational sales grew 14.7%*, with the acquisition of Abiomed contributing 4.8%. Consumer Health Consumer Health worldwide adjusted operational sales increased 7.7%* largely driven by over-the-counter (OTC) products. Major contributors to growth in OTC were TYLENOL and MOTRIN analgesics, upper respiratory products, international smoking cessation products, and IMODIUM in digestive health products. Additional contributors to growth were NEUTROGENA in Skin Health/Beauty products and Women’s Health products outside the United States. NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER: The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investors section of the company’s website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com. -- 3 of 24 -- Regulatory Janssen Marks First Approval Worldwide for AKEEGA (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations Press Release Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation Press Release Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH) Press Release Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma Press Release Data Release Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti-PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle- Invasive Bladder Cancer Press Release First Phase 3 TREMFYA (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis Press Release New Data Published on Biosense Webster QDOT MICRO Catheter – the Latest Advancement in Focal RF Ablation for Treating AFib Press Release Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors Press Release New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Press Release Janssen Announces Positive Topline Results for JNJ-2113—a Novel, First and Only Oral IL- 23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis1 Press Release Treatment with RYBREVANT (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer1 Press Release Other Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow Press Release Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies Press Release 1 Subsequent to the quarter -- 4 of 24 -- FULL-YEAR 2023 GUIDANCE: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) July 2023 April 2023 Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point 6.0% – 7.0% / 6.5% 4.5% – 5.5% / 5.0% Operational Sales2,5/ Mid-point Change vs. Prior Year / Mid-point $99.3B – $100.3B / $99.8B 7.0% – 8.0% / 7.5% $97.9B – $98.9B / $98.4B 5.5% – 6.5% / 6.0% Estimated Reported Sales3,5/ Mid-point Change vs. Prior Year / Mid-point $98.8B – $99.8B / $99.3B 6.5% – 7.5% / 7.0% $97.9B – $98.9B / $98.4B 5.5% – 6.5% / 6.0% Adjusted Operational EPS (Diluted)2,4/ Mid-point Change vs. Prior Year / Mid-point $10.60 – $10.70 / $10.65 4.5% – 5.5% / 5.0% $10.50 – $10.60 / $10.55 3.5% – 4.5% / 4.0% Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point $10.70 – $10.80 / $10.75 5.5% – 6.5% / 6.0% $10.60 – $10.70 / $10.65 4.5% – 5.5% / 5.0% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: July 2023 = $1.09 and April 2023 = $1.10 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items 5 Excludes COVID-19 Vaccine Note: percentages may have been rounded Other modeling considerations will be provided on the webcast. WEBCAST INFORMATION: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations. -- 5 of 24 -- ABOUT JOHNSON & JOHNSON: At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. NON-GAAP FINANCIAL MEASURES: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly results. Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the company's website at quarterly results. NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by -- 6 of 24 -- competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Press Contacts: Investor Contacts: Tesia Williams Jessica Moore media-relations@its.jnj.com investor-relations@its.jnj.com -- 7 of 24 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Sales to customers by segment of business Consumer Health U.S. 1,787 $ 1,687 6.0 % 6.0 - 3,522 $ 3,244 8.6 % 8.6 - International 2,224 2,118 5.0 9.0 (4.0) 4,341 4,147 4.7 10.1 (5.4) 4,011 3,805 5.4 7.7 (2.3) 7,863 7,391 6.4 9.5 (3.1) Pharmaceutical (1) U.S. 7,818 7,159 9.2 9.2 - 14,841 13,791 7.6 7.6 - International 5,913 6,158 (4.0) (2.5) (1.5) 12,303 12,395 (0.7) 3.1 (3.8) 13,731 13,317 3.1 3.8 (0.7) 27,144 26,186 3.7 5.5 (1.8) Pharmaceutical excluding COVID-19 Vaccine (1) U.S. 7,818 7,114 9.9 9.9 - 14,841 13,671 8.6 8.6 - International 5,628 5,659 (0.5) 1.5 (2.0) 11,271 11,514 (2.1) 1.9 (4.0) 13,446 12,773 5.3 6.2 (0.9) 26,112 25,185 3.7 5.5 (1.8) MedTech (1) U.S. 3,839 3,351 14.6 14.6 - 7,598 6,576 15.5 15.5 - International 3,949 3,547 11.3 14.7 (3.4) 7,671 7,293 5.2 10.3 (5.1) 7,788 6,898 12.9 14.7 (1.8) 15,269 13,869 10.1 12.8 (2.7) U.S. 13,444 12,197 10.2 10.2 - 25,961 23,611 10.0 10.0 - International 12,086 11,823 2.2 4.7 (2.5) 24,315 23,835 2.0 6.5 (4.5) Worldwide 25,530 24,020 6.3 7.5 (1.2) 50,276 47,446 6.0 8.2 (2.2) U.S. 13,444 12,152 10.6 10.6 - 25,961 23,491 10.5 10.5 - International 11,801 11,324 4.2 7.0 (2.8) 23,283 22,954 1.4 6.1 (4.7) Worldwide excluding COVID-19 Vaccine (1) 25,245 $ 23,476 7.5 % 8.9 (1.4) 49,244 $ 46,445 6.0 % 8.3 (2.3) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales reconciliation schedule SECOND QUARTER SIX MONTHS Percent Change -- 8 of 24 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Sales to customers by geographic area U.S. 13,444 $ 12,197 10.2 % 10.2 - 25,961 $ 23,611 10.0 % 10.0 - Europe 5,894 6,085 (3.1) (3.9) 0.8 12,226 12,109 1.0 3.0 (2.0) Western Hemisphere excluding U.S. 1,713 1,536 11.5 17.7 (6.2) 3,300 3,018 9.3 16.1 (6.8) Asia-Pacific, Africa 4,479 4,202 6.6 12.5 (5.9) 8,789 8,708 0.9 8.2 (7.3) International 12,086 11,823 2.2 4.7 (2.5) 24,315 23,835 2.0 6.5 (4.5) Worldwide 25,530 $ 24,020 6.3 % 7.5 (1.2) 50,276 $ 47,446 6.0 % 8.2 (2.2) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. SECOND QUARTER SIX MONTHS Percent Change -- 9 of 24 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 25,530 $ 100.0 24,020 $ 100.0 6.3 Cost of products sold 8,212 32.2 7,919 33.0 3.7 Gross Profit 17,318 67.8 16,101 67.0 7.6 Selling, marketing and administrative expenses 6,665 26.1 6,226 25.9 7.1 Research and development expense 3,829 15.0 3,703 15.4 3.4 Interest (income) expense, net (23) (0.1) (26) (0.1) Other (income) expense, net* (60) (0.2) 273 1.1 Restructuring 145 0.5 85 0.4 Earnings before provision for taxes on income 6,762 26.5 5,840 24.3 15.8 Provision for taxes on income 1,618 6.4 1,026 4.3 57.7 Net earnings 5,144 $ 20.1 4,814 $ 20.0 6.9 Net earnings per share (Diluted) 1.96 $ 1.80 $ 8.9 Average shares outstanding (Diluted) 2,625.7 2,667.9 Effective tax rate 23.9 % 17.6 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 8,824 $ 34.6 8,171 $ 34.0 8.0 Net earnings 7,358 $ 28.8 6,912 $ 28.8 6.5 Net earnings per share (Diluted) 2.80 $ 2.59 $ 8.1 Effective tax rate 16.6 % 15.4 % (1) See Reconciliation of Non-GAAP Financial Measures. SECOND QUARTER 2023 2022 * Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter. -- 10 of 24 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 50,276 $ 100.0 47,446 $ 100.0 6.0 Cost of products sold 16,607 33.0 15,517 32.7 7.0 Gross Profit 33,669 67.0 31,929 67.3 5.4 Selling, marketing and administrative expenses 12,803 25.5 12,164 25.6 5.3 Research and development expense 7,392 14.7 7,165 15.1 3.2 In-process research and development 49 0.1 610 1.3 Interest (income) expense, net (43) (0.1) (38) (0.1) Other (income) expense, net* 7,168 14.3 171 0.4 Restructuring 275 0.5 155 0.3 Earnings before provision for taxes on income 6,025 12.0 11,702 24.7 (48.5) Provision for taxes on income 949 1.9 1,739 3.7 (45.4) Net earnings 5,076 $ 10.1 9,963 $ 21.0 (49.1) Net earnings per share (Diluted) 1.93 $ 3.73 $ (48.3) Average shares outstanding (Diluted) 2,630.7 2,669.2 Effective tax rate 15.8 % 14.9 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income 17,292 $ 34.4 16,389 $ 34.5 5.5 Net earnings 14,426 $ 28.7 14,041 $ 29.6 2.7 Net earnings per share (Diluted) 5.48 $ 5.26 $ 4.2 Effective tax rate 16.6 % 14.3 % (1) See Reconciliation of Non-GAAP Financial Measures. SIX MONTHS 2023 2022 * Fiscal six months Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter. -- 11 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2023 2022 2023 2022 $5,144 $4,814 $5,076 $9,963 137 385 7,037 385 1,211 1,095 2,415 2,203 165 276 609 276 282 268 582 370 145 128 275 200 85 70 149 130 38 - 80 - (1) 109 71 520 - - 49 610 - - - (7) (373) (313) (2,430) (706) 546 2 557 98 (21) 78 (44) (1) $7,358 $6,912 $14,426 $14,041 2,625.7 2,667.9 2,630.7 2,669.2 $2.80 $2.59 $5.48 $5.26 Net Earnings, after tax- as reported Pre-tax Adjustments Litigation related Intangible Asset Amortization expense COVID-19 Vaccine related costs 1 Consumer Health separation costs Restructuring related 2 Medical Device Regulation 3 Acquisition, integration and divestiture related (Gains)/losses on securities IPR&D Other Tax Adjustments Tax impact on special item adjustments 4 Consumer Health separation tax related costs Tax legislation and other tax related Adjusted Net Earnings, after tax Average shares outstanding (Diluted) Adjusted net earnings per share (Diluted) Operational adjusted net earnings per share (Diluted) $2.84 $5.59 Notes: 1 2 3 4 Second Quarter Six Months Ended COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments. In the first and second quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $145 million in the quarter ($275 million Q2 YTD) include the termination of partnered and non-partnered program costs and asset impairments. The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024. -- 12 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported 5.4% 3.1% 12.9% 6.3% U.S. 6.0% 9.2% 14.6% 10.2% International 5.0% (4.0)% 11.3% 2.2% WW Currency (2.3) (0.7) (1.8) (1.2) U.S. - - - - International (4.0) (1.5) (3.4) (2.5) WW Operational 7.7% 3.8% 14.7% 7.5% U.S. 6.0% 9.2% 14.6% 10.2% International 9.0% (2.5)% 14.7% 4.7% Abiomed (4.8) (1.4) U.S. (8.1) (2.2) International (1.7) (0.5) All Other Acquisitions and Divestitures 0.0 0.1 0.0 0.1 U.S. 0.0 0.0 0.0 0.0 International 0.0 0.3 0.0 0.2 WW Adjusted Operational 7.7% 3.9% 9.9% 6.2% U.S. 6.0% 9.2% 6.5% 8.0% International 9.0% (2.2)% 13.0% 4.4% Adjusted Operational Sales Growth SECOND QUARTER 2023 ACTUAL vs. 2022 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 13 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical MedTech Total WW As Reported 6.4% 3.7% 10.1% 6.0% U.S. 8.6% 7.6% 15.5% 10.0% International 4.7% (0.7)% 5.2% 2.0% WW Currency (3.1) (1.8) (2.7) (2.2) U.S. - - - - International (5.4) (3.8) (5.1) (4.5) WW Operational 9.5% 5.5% 12.8% 8.2% U.S. 8.6% 7.6% 15.5% 10.0% International 10.1% 3.1% 10.3% 6.5% Abiomed (4.7) (1.4) U.S. (8.2) (2.3) International (1.6) (0.5) All Other Acquisitions and Divestitures 0.0 0.1 0.0 0.1 U.S. 0.0 0.0 0.0 0.0 International 0.0 0.3 0.0 0.2 WW Adjusted Operational 9.5% 5.6% 8.1% 6.9% U.S. 8.6% 7.6% 7.3% 7.7% International 10.1% 3.4% 8.7% 6.2% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth SIX MONTHS 2023 ACTUAL vs. 2022 ACTUAL Segments -- 14 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2) OTC US 712 $ 663 7.5% 7.5% - 1,457 $ 1,333 9.3% 9.3% - Intl 947 818 15.7% 19.0% -3.3% 1,844 1,609 14.6% 19.4% -4.8% WW 1,659 1,482 12.0% 13.9% -1.9% 3,301 2,943 12.2% 14.8% -2.6% SKIN HEALTH / BEAUTY US 650 629 3.4% 3.4% - 1,267 1,173 8.0% 8.0% - Intl 498 497 0.3% 3.8% -3.5% 991 965 2.7% 8.1% -5.4% WW 1,148 1,126 2.0% 3.5% -1.5% 2,258 2,138 5.6% 8.0% -2.4% ORAL CARE US 173 170 1.7% 1.7% - 332 313 6.2% 6.2% - Intl 225 224 0.3% 3.4% -3.1% 427 447 -4.7% -0.3% -4.4% WW 398 394 0.9% 2.7% -1.8% 759 760 -0.2% 2.4% -2.6% BABY CARE US 99 88 12.5% 12.5% - 195 173 12.7% 12.7% - Intl 261 287 -9.1% -4.0% -5.1% 524 557 -6.0% 0.1% -6.1% WW 360 375 -4.0% -0.2% -3.8% 719 730 -1.6% 3.1% -4.7% WOMEN'S HEALTH US 4 3 -2.1% -2.1% - 7 7 -0.1% -0.1% - Intl 235 228 3.5% 10.2% -6.7% 449 452 -0.7% 7.2% -7.9% WW 238 230 3.4% 10.0% -6.6% 455 458 -0.6% 7.1% -7.7% WOUND CARE / OTHER US 149 133 12.3% 12.3% - 264 245 7.9% 7.9% - Intl 58 65 -10.3% -4.6% -5.7% 107 117 -8.4% -1.5% -6.9% WW 207 197 4.9% 6.8% -1.9% 371 361 2.6% 4.9% -2.3% TOTAL CONSUMER HEALTH US 1,787 1,687 6.0% 6.0% - 3,522 3,244 8.6% 8.6% - Intl 2,224 2,118 5.0% 9.0% -4.0% 4,341 4,147 4.7% 10.1% -5.4% WW 4,011 $ 3,805 5.4% 7.7% -2.3% 7,863 $ 7,391 6.4% 9.5% -3.1% See footnotes at end of schedule % Change % Change -- 15 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS PHARMACEUTICAL SEGMENT (2,3) 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency IMMUNOLOGY US 2,865 $ 2,853 0.4% 0.4% - 5,313 $ 5,354 -0.8% -0.8% - Intl 1,631 1,559 4.7% 6.6% -1.9% 3,295 3,176 3.8% 8.2% -4.4% WW 4,496 4,411 1.9% 2.6% -0.7% 8,608 8,530 0.9% 2.6% -1.7% REMICADE US 277 391 -29.3% -29.3% - 553 749 -26.2% -26.2% - US Exports (4) 33 44 -24.9% -24.9% - 74 124 -40.3% -40.3% - Intl 152 212 -28.2% -25.2% -3.0% 322 437 -26.2% -22.5% -3.7% WW 462 647 -28.6% -27.6% -1.0% 949 1,310 -27.5% -26.3% -1.2% SIMPONI / SIMPONI ARIA US 285 301 -5.1% -5.1% - 556 588 -5.4% -5.4% - Intl 244 266 -8.2% -4.3% -3.9% 510 549 -7.1% -1.1% -6.0% WW 529 566 -6.6% -4.7% -1.9% 1,066 1,137 -6.2% -3.3% -2.9% STELARA US 1,817 1,731 4.9% 4.9% - 3,268 3,110 5.1% 5.1% - Intl 981 868 13.0% 14.1% -1.1% 1,974 1,777 11.1% 15.2% -4.1% WW 2,797 2,599 7.6% 8.0% -0.4% 5,241 4,887 7.2% 8.7% -1.5% TREMFYA US 450 382 17.8% 17.8% - 856 773 10.7% 10.7% - Intl 255 214 19.4% 21.0% -1.6% 489 413 18.4% 22.8% -4.4% WW 706 597 18.3% 18.9% -0.6% 1,346 1,187 13.4% 15.0% -1.6% OTHER IMMUNOLOGY US 4 3 17.8% 17.8% - 7 9 -30.2% -30.2% - Intl 0 0 - - - 0 0 - - - WW 4 3 17.8% 17.8% - 7 9 -30.2% -30.2% - INFECTIOUS DISEASES US 395 415 -4.9% -4.9% - 787 876 -10.2% -10.2% - Intl 727 901 -19.4% -22.0% 2.6% 1,920 1,737 10.5% 12.3% -1.8% WW 1,121 1,316 -14.8% -16.6% 1.8% 2,707 2,613 3.6% 4.7% -1.1% COVID-19 VACCINE US - 45 * * - - 120 * * - Intl 285 499 -43.0% -47.4% 4.4% 1,032 881 17.1% 18.4% -1.3% WW 285 544 -47.7% -51.8% 4.1% 1,032 1,001 3.0% 4.2% -1.2% EDURANT / rilpivirine US 8 9 -9.0% -9.0% - 17 18 -5.3% -5.3% - Intl 258 215 19.9% 17.3% 2.6% 529 454 16.4% 18.0% -1.6% WW 266 225 18.6% 16.2% 2.4% 546 473 15.6% 17.1% -1.5% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 382 355 7.6% 7.6% - 760 724 5.0% 5.0% - Intl 109 110 -0.2% -1.0% 0.8% 208 242 -13.9% -12.1% -1.8% WW 491 464 5.8% 5.6% 0.2% 968 965 0.3% 0.7% -0.4% OTHER INFECTIOUS DISEASES US 5 6 -27.2% -27.2% - 10 14 -30.6% -30.6% - Intl 74 77 -3.5% 3.6% -7.1% 151 160 -5.6% -1.2% -4.4% WW 79 83 -5.2% 1.3% -6.5% 161 174 -7.6% -3.6% -4.0% % Change % Change -- 16 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency NEUROSCIENCE US 1,029 896 14.9% 14.9% - 2,007 1,739 15.4% 15.4% - Intl 764 837 -8.8% -4.6% -4.2% 1,590 1,735 -8.4% -3.8% -4.6% WW 1,793 1,734 3.5% 5.5% -2.0% 3,597 3,475 3.5% 5.8% -2.3% CONCERTA / Methylphenidate US 64 38 68.2% 68.2% - 134 73 84.0% 84.0% - Intl 143 123 16.3% 21.3% -5.0% 279 245 13.9% 20.7% -6.8% WW 208 161 28.6% 32.4% -3.8% 414 318 30.0% 35.3% -5.3% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 721 691 4.3% 4.3% - 1,434 1,352 6.0% 6.0% - Intl 310 362 -14.4% -12.6% -1.8% 641 749 -14.5% -10.7% -3.8% WW 1,031 1,054 -2.1% -1.5% -0.6% 2,075 2,102 -1.3% 0.1% -1.4% SPRAVATO US 144 74 93.2% 93.2% - 255 135 88.3% 88.3% - Intl 25 11 * * * 45 20 * * * WW 169 85 98.2% 98.5% -0.3% 300 155 93.1% 93.8% -0.7% OTHER NEUROSCIENCE US 100 93 9.3% 9.3% - 184 179 3.1% 3.1% - Intl 286 341 -16.4% -9.9% -6.5% 625 721 -13.4% -8.7% -4.7% WW 386 433 -10.9% -5.8% -5.1% 809 900 -10.1% -6.4% -3.7% ONCOLOGY US 2,069 1,679 23.2% 23.2% - 3,958 3,261 21.4% 21.4% - Intl 2,329 2,362 -1.4% 0.1% -1.5% 4,552 4,731 -3.8% 0.0% -3.8% WW 4,398 4,042 8.8% 9.7% -0.9% 8,510 7,992 6.5% 8.8% -2.3% CARVYKTI US 114 24 * * - 184 24 * * - Intl 3 - * * * 5 - * * * WW 117 24 * * * 189 24 * * * DARZALEX US 1,322 1,021 29.5% 29.5% - 2,513 1,974 27.3% 27.3% - Intl 1,110 965 15.0% 17.0% -2.0% 2,182 1,868 16.8% 21.5% -4.7% WW 2,431 1,986 22.4% 23.4% -1.0% 4,695 3,842 22.2% 24.5% -2.3% ERLEADA US 241 233 3.6% 3.6% - 490 439 11.8% 11.8% - Intl 326 218 49.7% 51.7% -2.0% 619 412 50.3% 55.9% -5.6% WW 567 450 25.9% 26.9% -1.0% 1,109 850 30.4% 33.2% -2.8% IMBRUVICA US 262 349 -24.9% -24.9% - 532 719 -26.0% -26.0% - Intl 579 620 -6.7% -5.7% -1.0% 1,136 1,288 -11.8% -8.8% -3.0% WW 841 970 -13.2% -12.6% -0.6% 1,668 2,008 -16.9% -15.0% -1.9% ZYTIGA / abiraterone acetate US 9 19 -55.2% -55.2% - 25 38 -34.7% -34.7% - Intl 218 486 -55.1% -53.8% -1.3% 447 1,006 -55.6% -53.0% -2.6% WW 227 505 -55.1% -53.8% -1.3% 472 1,044 -54.8% -52.3% -2.5% OTHER ONCOLOGY US 122 33 * * - 214 67 * * - Intl 92 72 27.8% 29.4% -1.6% 162 156 3.6% 7.1% -3.5% WW 214 106 * * * 376 224 68.0% 70.4% -2.4% % Change % Change -- 17 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency PULMONARY HYPERTENSION US 684 560 22.0% 22.0% - 1,284 1,132 13.4% 13.4% - Intl 289 284 2.0% 5.7% -3.7% 561 563 -0.4% 5.5% -5.9% WW 972 843 15.3% 16.5% -1.2% 1,844 1,695 8.8% 10.8% -2.0% OPSUMIT US 328 265 23.7% 23.7% - 601 538 11.6% 11.6% - Intl 179 173 3.4% 6.0% -2.6% 346 343 0.9% 6.1% -5.2% WW 507 438 15.7% 16.7% -1.0% 947 881 7.5% 9.5% -2.0% UPTRAVI US 338 272 24.2% 24.2% - 642 541 18.7% 18.7% - Intl 61 56 10.0% 14.1% -4.1% 119 112 6.6% 11.7% -5.1% WW 399 328 21.8% 22.5% -0.7% 761 653 16.6% 17.5% -0.9% OTHER PULMONARY HYPERTENSION US 18 23 -23.8% -23.8% - 41 53 -23.0% -23.0% - Intl 48 55 -10.9% -3.7% -7.2% 95 108 -11.7% -2.8% -8.9% WW 66 78 -14.7% -9.7% -5.0% 136 161 -15.5% -9.5% -6.0% CARDIOVASCULAR / METABOLISM / OTHER US 776 757 2.6% 2.6% - 1,491 1,429 4.3% 4.3% - Intl 174 215 -19.0% -18.3% -0.7% 386 453 -14.7% -12.0% -2.7% WW 950 972 -2.2% -2.0% -0.2% 1,877 1,882 -0.3% 0.4% -0.7% XARELTO US 637 609 4.7% 4.7% - 1,215 1,117 8.8% 8.8% - Intl - - - - - - - - - - WW 637 609 4.7% 4.7% - 1,215 1,117 8.8% 8.8% - OTHER US 138 148 -6.3% -6.3% - 275 312 -11.8% -11.8% - Intl 174 215 -19.0% -18.3% -0.7% 386 453 -14.7% -12.0% -2.7% WW 313 363 -13.8% -13.4% -0.4% 662 765 -13.5% -11.9% -1.6% TOTAL PHARMACEUTICAL US 7,818 7,159 9.2% 9.2% - 14,841 13,791 7.6% 7.6% - Intl 5,913 6,158 -4.0% -2.5% -1.5% 12,303 12,395 -0.7% 3.1% -3.8% WW 13,731 $ 13,317 3.1% 3.8% -0.7% 27,144 $ 26,186 3.7% 5.5% -1.8% See footnotes at end of schedule % Change % Change -- 18 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS MEDTECH SEGMENT (2,3) 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 908 $ 525 73.1% 73.1% - 1,771 $ 1,019 73.8% 73.8% - Intl 712 525 35.7% 40.7% -5.0% 1,352 1,123 20.5% 27.0% -6.5% WW 1,620 1,049 54.4% 56.9% -2.5% 3,123 2,141 45.8% 49.3% -3.5% ELECTROPHYSIOLOGY US 609 499 22.0% 22.0% - 1,180 969 21.7% 21.7% - Intl 587 469 25.1% 30.0% -4.9% 1,109 1,001 10.8% 17.3% -6.5% WW 1,196 968 23.5% 25.9% -2.4% 2,288 1,970 16.2% 19.5% -3.3% ABIOMED US 272 - * * - 536 - * * - Intl 59 - * * * 119 - * * * WW 331 - * * * 655 - * * * OTHER INTERVENTIONAL SOLUTIONS US 27 26 4.5% 4.5% - 55 50 10.8% 10.8% - Intl 67 56 20.0% 25.3% -5.3% 125 121 2.8% 8.9% -6.1% WW 93 81 15.1% 18.8% -3.7% 180 171 5.1% 9.5% -4.4% ORTHOPAEDICS US 1,388 1,338 3.7% 3.7% - 2,751 2,627 4.7% 4.7% - Intl 878 820 7.0% 9.0% -2.0% 1,759 1,719 2.3% 6.4% -4.1% WW 2,265 2,157 5.0% 5.7% -0.7% 4,510 4,345 3.8% 5.4% -1.6% HIPS US 250 240 4.1% 4.1% - 491 465 5.6% 5.6% - Intl 147 148 -0.8% 1.2% -2.0% 296 312 -5.1% -1.3% -3.8% WW 397 388 2.2% 3.0% -0.8% 787 777 1.3% 2.8% -1.5% KNEES US 221 216 2.4% 2.4% - 447 417 7.2% 7.2% - Intl 142 133 6.3% 8.0% -1.7% 284 271 4.8% 8.8% -4.0% WW 363 349 3.9% 4.5% -0.6% 731 688 6.3% 7.9% -1.6% TRAUMA US 483 464 4.3% 4.3% - 974 939 3.7% 3.7% - Intl 255 232 9.9% 10.9% -1.0% 522 505 3.2% 7.0% -3.8% WW 739 696 6.1% 6.5% -0.4% 1,496 1,444 3.6% 4.9% -1.3% SPINE, SPORTS & OTHER US 433 418 3.5% 3.5% - 839 805 4.1% 4.1% - Intl 334 306 9.0% 11.6% -2.6% 657 630 4.2% 8.7% -4.5% WW 766 724 5.8% 7.0% -1.2% 1,495 1,436 4.2% 6.1% -1.9% % Change % Change -- 19 of 24 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2023 2022 Reported Operational (1) Currency 2023 2022 Reported Operational (1) Currency SURGERY US 1,015 992 2.2% 2.2% - 1,990 1,913 4.0% 4.0% - Intl 1,580 1,458 8.4% 12.6% -4.2% 3,039 2,971 2.3% 7.7% -5.4% WW 2,594 2,450 5.9% 8.4% -2.5% 5,028 4,884 3.0% 6.3% -3.3% ADVANCED US 466 454 2.7% 2.7% - 910 871 4.5% 4.5% - Intl 757 702 7.8% 12.1% -4.3% 1,430 1,431 0.0% 5.3% -5.3% WW 1,222 1,156 5.8% 8.4% -2.6% 2,340 2,302 1.7% 5.0% -3.3% GENERAL US 548 538 1.9% 1.9% - 1,079 1,042 3.6% 3.6% - Intl 823 756 8.9% 13.1% -4.2% 1,608 1,540 4.5% 10.0% -5.5% WW 1,372 1,294 6.0% 8.4% -2.4% 2,688 2,582 4.1% 7.4% -3.3% VISION US 529 496 6.6% 6.6% - 1,087 1,017 6.9% 6.9% - Intl 778 745 4.6% 7.1% -2.5% 1,521 1,481 2.7% 7.5% -4.8% WW 1,308 1,241 5.4% 6.9% -1.5% 2,608 2,498 4.4% 7.2% -2.8% CONTACT LENSES / OTHER US 409 374 9.1% 9.1% - 853 774 10.1% 10.1% - Intl 530 519 2.2% 4.8% -2.6% 1,039 1,030 0.9% 6.3% -5.4% WW 939 894 5.1% 6.6% -1.5% 1,892 1,804 4.9% 8.0% -3.1% SURGICAL US 120 122 -1.1% -1.1% - 234 243 -3.6% -3.6% - Intl 249 225 10.1% 12.3% -2.2% 482 451 6.7% 10.2% -3.5% WW 369 347 6.2% 7.6% -1.4% 716 694 3.1% 5.4% -2.3% TOTAL MEDTECH US 3,839 3,351 14.6% 14.6% - 7,598 6,576 15.5% 15.5% - Intl 3,949 3,547 11.3% 14.7% -3.4% 7,671 7,293 5.2% 10.3% -5.1% WW 7,788 $ 6,898 12.9% 14.7% -1.8% 15,269 $ 13,869 10.1% 12.8% -2.7% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change % Change -- 20 of 24 -- 2023 2022 Total Operations Currency 2023 2022 Total Operations Currency Pharmaceutical U.S. 7,818 $ 7,159 9.2 % 9.2 - 14,841 $ 13,791 7.6 % 7.6 - International 5,913 6,158 (4.0) (2.5) (1.5) 12,303 12,395 (0.7) 3.1 (3.8) Worldwide 13,731 13,317 3.1 3.8 (0.7) 27,144 26,186 3.7 5.5 (1.8) COVID-19 Vaccine U.S. - 45 * * - - 120 * * - International 285 499 (43.0) (47.4) 4.4 1,032 881 17.1 18.4 (1.3) Worldwide 285 544 (47.7) (51.8) 4.1 1,032 1,001 3.0 4.2 (1.2) Pharmaceutical excluding COVID-19 Vaccine U.S. 7,818 7,114 9.9 9.9 - 14,841 13,671 8.6 8.6 - International 5,628 5,659 (0.5) 1.5 (2.0) 11,271 11,514 (2.1) 1.9 (4.0) Worldwide 13,446 12,773 5.3 6.2 (0.9) 26,112 25,185 3.7 5.5 (1.8) Worldwide U.S. 13,444 12,197 10.2 10.2 - 25,961 23,611 10.0 10.0 - International 12,086 11,823 2.2 4.7 (2.5) 24,315 23,835 2.0 6.5 (4.5) Worldwide 25,530 24,020 6.3 7.5 (1.2) 50,276 47,446 6.0 8.2 (2.2) COVID-19 Vaccine U.S. - 45 * * - - 120 * * - International 285 499 (43.0) (47.4) 4.4 1,032 881 17.1 18.4 (1.3) Worldwide 285 544 (47.7) (51.8) 4.1 1,032 1,001 3.0 4.2 (1.2) Worldwide U.S. 13,444 12,152 10.6 10.6 - 25,961 23,491 10.5 10.5 - International 11,801 11,324 4.2 7.0 (2.8) 23,283 22,954 1.4 6.1 (4.7) Worldwide excluding COVID-19 Vaccine 25,245 $ 23,476 7.5 % 8.9 (1.4) 49,244 $ 46,445 6.0 % 8.3 (2.3) Note: Columns and rows within tables may not add due to rounding * Percentage greater than 100% or not meaningful Supplemental Sales Reconciliation (Unaudited) (Dollars in Millions) SECOND QUARTER SIX MONTHS Percent Change Percent Change -- 21 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 Reported Income Before Tax by Segment $ 860 784 4,862 4,420 1,699 1,141 (377) (237) (282) (268) 6,762 5,840 % to Sales 21.4% 20.6% 35.4% 33.2% 21.8% 16.5% -1.5% -1.0% -1.1% -1.1% 26.5% 24.3% Intangible asset amortization expense 81 100 748 736 382 259 - - - - 1,211 1,095 In-process research and development - - - - - - - - - - - - Litigation related - 78 (93) 36 60 271 170 - - - 137 385 COVID-19 Vaccine related costs - - 165 276 - - - - - - 165 276 Loss/(gain) on securities - - 38 102 (39) 7 - - - - (1) 109 Restructuring related - 25 145 23 - 80 - - - - 145 128 Acquisition, integration and divestiture related - - - - 38 - - - - - 38 - Medical Device Regulation - - - - 85 70 - - - - 85 70 Consumer Health separation costs - - - - - - - - 282 268 282 268 - Other - - - - - - - - - - - Adjusted Income Before Tax by Segment $ 941 987 5,865 5,593 2,225 1,828 (207) (237) - - 8,824 8,171 % to Sales 23.5% 25.9% 42.7% 42.0% 28.6% 26.5% -0.8% -1.0% 0.0% 0.0% 34.6% 34.0% *Estimated as of 7/20/2023 Q2 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Separation Costs Consumer Health Pharmaceutical MedTech Unallocated Worldwide Total -- 22 of 24 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 Reported Income Before Tax by Segment $ 1,636 1,470 9,306 8,344 3,144 2,618 (7,479) (360) (582) (370) 6,025 11,702 % to Sales 20.8% 19.9% 34.3% 31.9% 20.6% 18.9% -14.9% -0.8% -1.2% -0.8% 12.0% 24.7% Intangible asset amortization expense 163 194 1,487 1,496 765 513 - - - - 2,415 2,203 In-process research and development - - - 610 49 - - - - - 49 610 Litigation related - 78 (93) 36 60 271 7,070 - - - 7,037 385 COVID-19 Vaccine related costs - - 609 276 - - - - - - 609 276 Loss/(gain) on securities - - 76 496 (5) 24 - - - - 71 520 Restructuring related - 39 275 9 - 152 - - - - 275 200 Acquisition, integration and divestiture related - - - - 80 - - - - - 80 - Medical Device Regulation - - - - 149 130 - - - - 149 130 Consumer Health separation costs - - - - - - - - 582 370 582 370 Other - - - - - - - (7) - - - (7) Adjusted Income Before Tax by Segment $ 1,799 1,781 11,660 11,267 4,242 3,708 (409) (367) - - 17,292 16,389 % to Sales 22.9% 24.1% 43.0% 43.0% 27.8% 26.7% -0.8% -0.8% 0.0% 0.0% 34.4% 34.5% *Estimated as of 7/20/2023 Q2 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Separation Costs Consumer Health Pharmaceutical MedTech Unallocated Worldwide Total -- 23 of 24 -- Second Quarter Second Quarter July 2, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other July 3, 2022 Non-GAAP Cost of products sold 8,212 $ (1,211) - (34) 38 (14) - - - 6,991 Selling, marketing and admin expenses 6,665 (8) (44) 6,613 Research and development expense 3,829 - (44) (46) (2) 3,737 Other (Income) / Expense (60) - (137) - (38) 1 (156) (221) - - (611) In-process research and development - - - Interest (Income)/Expense (23) (1) (24) Restructuring 145 (145) - Provision for taxes on income 1,618 194 29 - 37 12 (1) 15 38 49 (546) 21 - 1,466 Net Earnings 5,144 1,017 108 - 108 26 - 71 126 233 546 (21) - 7,358 Second Quarter Second Quarter July 3, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other July 3, 2022 Non-GAAP Cost of products sold 7,919 $ (1,083) (17) (25) (194) - - - - 6,600 Selling, marketing and admin expenses 6,226 (6) 6,220 Research and development expense 3,703 - (39) (110) 3,554 Other (Income) / Expense 273 (12) (385) (26) - (109) 28 (268) - - (499) In-process research and development - - - Restructuring 85 (85) - Provision for taxes on income 1,026 170 (29) - 25 - 25 13 65 44 (2) (78) - 1,259 Net Earnings 4,814 925 414 - 103 - 84 57 211 224 2 78 - 6,912 Six Months Six Months July 2, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other July 2, 2023 Non-GAAP Cost of products sold 16,607 $ (2,411) - (57) (168) (26) 13,945 Selling, marketing and admin expenses 12,803 (15) (82) 12,706 Research and development expense 7,392 (16) (78) (62) (4) 7,232 Other (Income) / Expense 7,168 (4) (7,037) - (64) (71) (378) (506) - - (892) In-process research and development 49 (49) - - - Interest (Income)/Expense (43) 36 (7) Restructuring 275 (275) - Provision for taxes on income 949 388 1,651 11 69 17 15 27 143 109 (557) 44 - 2,866 Net Earnings 5,076 2,027 5,386 38 206 63 56 123 465 473 557 (44) - 14,426 Six Months Six Months July 3, 2022 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Other July 3, 2022 Non-GAAP Cost of products sold 15,517 $ (2,191) (33) (47) (194) 13,052 Selling, marketing and admin expenses 12,164 (12) 12,152 Research and development expense 7,165 - (71) (110) 6,984 Other (Income) / Expense 171 (12) (385) (12) - (520) 28 (370) - 7 (1,093) In-process research and development 610 (610) - Restructuring 155 (155) - Provision for taxes on income 1,739 338 (82) 138 37 - 121 24 65 67 (98) 1 (2) 2,348 Net Earnings 9,963 1,865 467 472 163 - 399 106 211 303 98 (1) (5) 14,041 Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Year to Date Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related Tax legislation and other tax related Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs Tax legislation and other tax related Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date Consumer Health separation tax related costs In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Consumer Health separation costs -- 24 of 24 --